• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

141
19
13
13
11

COUNTRY

5
4
4
4
3

PRICE

6
90
126
501

PUBLISHED

1
12
121
501

PRODUCT TYPE

491
5
2
1

Immune Disorders

(501 Products)

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Spain Drug...

November 2012
FROM

Humira (Rheumatoid Arthritis) Forecast and Market Analysis

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab...

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - France...

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Japan Drug...

November 2012
FROM

Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis

Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast...

November 2012
FROM

Simponi (Rheumatoid Arthritis) Forecast and Market Analysis

Simponi (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis

Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Tabalumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis

Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - China Drug...

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Australia...

November 2012
FROM

Orencia (Rheumatoid Arthritis) Forecast and Market Analysis

Orencia (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Orencia (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis

Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Actemra (Rheumatoid Arthritis) Forecast and Market Analysis

Actemra (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Actemra (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - India Drug...

November 2012
FROM

Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis

Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis

Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis. The...

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis...

November 2012
FROM

Remicade (Rheumatoid Arthritis) Forecast and Market Analysis

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab...

November 2012
FROM

Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis

Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis....

November 2012
FROM

PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update

PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Italy Drug...

November 2012
FROM
Loading Indicator

Our Clients

Merck & Co., Inc. Celgene Corporation GlaxoSmithKline PLC Genentech, Inc. Johnson & Johnson Services, Inc. ViiV Healthcare